March 16 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies including Alnylam Pharmaceuticals, Cogent Biosciences and Summit Therapeutics on Monday.
HIGHLIGHTS
* Alnylam Pharmaceuticals Inc ALNY.O: Jefferies assumes coverage with hold vs buy rating |
* Cogent Biosciences Inc COGT.O: Jefferies assumes coverage with buy rating |
* Summit Therapeutics Inc SMMT.O: Jefferies cuts to hold from buy |
Following is a summary of research actions on U.S. companies reported by Reuters on Monday. Stock entries are in alphabetical order.
* Abivax SA ABVX.O: Jefferies initiates coverage with buy rating; price target $160 |
* Alnylam Pharmaceuticals Inc ALNY.O: Jefferies assumes coverage with hold vs buy rating |
* Alnylam Pharmaceuticals Inc ALNY.O: Jefferies assumes coverage with PT $330 vs $522 |
* American Express Co AXP.N: BTIG cuts target price to $285 from $328 |
* Archrock Inc AROC.N: RBC raises target price to $40 from $32 |
* Bellring Brands Inc BRBR.N: Jefferies cuts target price to $28 from $38 |
* Brunswick Corp BC.N: JP Morgan raises target price to $78 from $73 |
* Cadre Holdings Inc CDRE.N: Jefferies cuts target price to $45 from $55 |
* Chevron Corp CVX.N: Jefferies raises target price to $227 from $189 |
* Coca-Cola Co KO.N: Jefferies raises target price to $90 from $87 |
* Cogent Biosciences Inc COGT.O: Jefferies assumes coverage with buy rating |
* Cogent Biosciences Inc COGT.O: Jefferies assumes coverage with price target $55 vs $48 |
* Design Therapeutics Inc DSGN.O: Jefferies initiates coverage with buy rating |
* Design Therapeutics Inc DSGN.O: Jefferies initiates coverage with price target $15 |
* Ecolab Inc ECL.N: Berenberg raises to buy from hold; raises PT to $326 from $300 |
* Exxon Mobil XOM.N: Jefferies raises target price to $178 from $149 |
* Fifth Third Bancorp FITB.O: JP Morgan resumes coverage with overweight rating |
* Fifth Third Bancorp FITB.O: JP Morgan resumes coverage with target price $50.5 vs $45 |
* Incyte INCY.O: Jefferies assumes coverage with hold vs buy rating; PT $94 vs $120 |
* Insmed Inc INSM.O: Jefferies assumes coverage with buy rating; price target $228 vs $219 |
* Kymera Therapeutics Inc KYMR.O: Jefferies assumes coverage with buy rating |
* Kymera Therapeutics Inc KYMR.O: Jefferies assumes coverage with PT $110 vs $122 |
* Macy's Inc M.N: Jefferies cuts target price to $22 from $27 |
* Marathon Petroleum Corp MPC.N: Jefferies raises target price to $263 from $205 |
* Micron Technology Inc MU.O: RBC raises target price to $525 from $425 |
* Pennymac Financial Services Inc PFSI.N: KBW raises to outperform from market perform |
* Phillips 66 PSX.N: Jefferies raises target price to $174 from $158 |
* Repay Holdings Corp RPAY.O: Canaccord Genuity cuts target price to $8 from $12 |
* Revolution Medicines Inc RVMD.O: Jefferies assumes coverage with buy rating |
* Revolution Medicines Inc RVMD.O: Jefferies assumes coverage with PT $140 vs $88 |
* Royal Caribbean Group RCL.N: JP Morgan raises target price to $376.00 from $371.00 |
* Rubrik Inc RBRK.N: CIBC cuts target price to $110 from $130 |
* Sentinelone Inc S.N: Berenberg cuts target price to $20.5 from $25 |
* Stellus Capital Investment Corp SCM.N: KBW cuts target price to $9 from $13 |
* Summit Therapeutics Inc SMMT.O: Jefferies cuts to hold from buy |
* Summit Therapeutics Inc SMMT.O: Jefferies cuts target price to $15 from $42 |
* Talos Energy Inc TALO.N: Gerdes Energy Research cuts to neutral from buy |
* Valero Energy Corp VLO.N: Jefferies raises target price to $272 from $216 |
(Compiled by Bengaluru Newsroom)
((Diaries@thomsonreuters.com))
Comments